semaglutide fda compounding Novo asks to prevent compounders from making GLP-1 knockoffs The End of Compounded Semaglutide:

Therapeutic strategies targeting ALDOB or fructose uptake could disrupt these interconnected pathways, offering a promising approach to counteract CRCs metabolic resilience and improve clinical outcomes [23]

AASLD 2017 Current Status of Pharmacologic Treatments for NASH No approved therapies for NASH Currently available therapeutics with (some) proven efficacy Vitamin E Pioglitazone NASH: targets for therapeutics Endpoints for clinical trials Disease Activity (steatohepatitis) = NAFLD Activity Score (NAS) Disease Progression = Fibrosis Stage Clinical outcomes : Cirrhosis (MELD, Portal hypertension), Liver-related outcome, death Adapted from Konerman MA

Decreased Appetite and Food Intake: If youre eating less or changing your diet because of the medication, you may not be consuming enough fiber or liquids, which can also contribute to constipation

its an investment in your confidence and well-being